Table 1 Patients’ baseline characteristics
From: Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
Characteristic | Value |
|---|---|
Age, median (range) | 51 (38 to 68) |
Eastern Cooperative Oncology Group performance status, number of patients | |
0 | 20 |
Histological subtype, number of patients | |
Comedo carcinoma | 7 |
Non-comedo carcinoma | 13 |
Pathological subtype, number of patients | |
Low grade | 0 |
Intermediate grade | 4 |
High grade | 16 |
Without necrosis | 4 |
Hormone receptor status, number of patients | |
Estrogen receptor-positive | 12 |
Estrogen receptor-negative | 7 |
Progesterone receptor-positive | 9 |
Progesterone receptor-negative | 10 |
Unknown | 1 |